Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free BIOG Stock Alerts

The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,546 -12.00 (-0.77%)
As of 08:45 AM Eastern
Compare

BIOG vs. GSS, AGT, VEIL, SOI, and EDIN

Should you buy The Biotech Growth Trust stock or one of its competitors? MarketBeat compares The Biotech Growth Trust with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with The Biotech Growth Trust include Genesis Emerging Markets Fund (GSS), AVI Global Trust (AGT), Vietnam Enterprise (VEIL), Schroder Oriental Income (SOI), and Edinburgh Investment (EDIN). These companies are all part of the "asset management" industry.

How does The Biotech Growth Trust compare to Genesis Emerging Markets Fund?

Genesis Emerging Markets Fund (LON:GSS) and The Biotech Growth Trust (LON:BIOG) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

The Biotech Growth Trust has a net margin of 96.47% compared to Genesis Emerging Markets Fund's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat Genesis Emerging Markets Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
Genesis Emerging Markets FundN/A N/A N/A
The Biotech Growth Trust 96.47%48.26%12.39%

The Biotech Growth Trust has lower revenue, but higher earnings than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genesis Emerging Markets Fund£250.40M0.00N/A£140.70N/A
The Biotech Growth Trust-£17.73M-16.92£83.83M£558.002.77

In the previous week, Genesis Emerging Markets Fund's average media sentiment score of 0.00 equaled The Biotech Growth Trust'saverage media sentiment score.

Company Overall Sentiment
Genesis Emerging Markets Fund Neutral
The Biotech Growth Trust Neutral

Summary

The Biotech Growth Trust beats Genesis Emerging Markets Fund on 6 of the 8 factors compared between the two stocks.

How does The Biotech Growth Trust compare to AVI Global Trust?

AVI Global Trust (LON:AGT) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

8.4% of AVI Global Trust shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.2% of AVI Global Trust shares are held by company insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AVI Global Trust has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than AVI Global Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVI Global Trust£127.64M7.98£215.81M£28.009.13
The Biotech Growth Trust-£17.73M-16.92£83.83M£558.002.77

The Biotech Growth Trust has a net margin of 96.47% compared to AVI Global Trust's net margin of 90.88%. The Biotech Growth Trust's return on equity of 48.26% beat AVI Global Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
AVI Global Trust90.88% 10.97% 7.00%
The Biotech Growth Trust 96.47%48.26%12.39%

AVI Global Trust has a beta of 0.95116794, meaning that its share price is 5% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, meaning that its share price is 40% less volatile than the broader market.

In the previous week, AVI Global Trust's average media sentiment score of 0.00 equaled The Biotech Growth Trust'saverage media sentiment score.

Company Overall Sentiment
AVI Global Trust Neutral
The Biotech Growth Trust Neutral

Summary

The Biotech Growth Trust beats AVI Global Trust on 6 of the 11 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Vietnam Enterprise?

The Biotech Growth Trust (LON:BIOG) and Vietnam Enterprise (LON:VEIL) are both small-cap financial services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

The Biotech Growth Trust has a net margin of 96.47% compared to Vietnam Enterprise's net margin of 96.37%. The Biotech Growth Trust's return on equity of 48.26% beat Vietnam Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
Vietnam Enterprise 96.37%19.70%-7.53%

In the previous week, Vietnam Enterprise's average media sentiment score of 0.15 beat The Biotech Growth Trust's score of 0.00 indicating that Vietnam Enterprise is being referred to more favorably in the news media.

Company Overall Sentiment
The Biotech Growth Trust Neutral
Vietnam Enterprise Neutral

The Biotech Growth Trust has a beta of 0.59646654, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Vietnam Enterprise has a beta of 0.432, suggesting that its share price is 57% less volatile than the broader market.

The Biotech Growth Trust has higher earnings, but lower revenue than Vietnam Enterprise. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Vietnam Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-16.92£83.83M£558.002.77
Vietnam Enterprise£81.16M13.06-£4.24M£40.0019.28

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 37.0% of Vietnam Enterprise shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 0.2% of Vietnam Enterprise shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

The Biotech Growth Trust beats Vietnam Enterprise on 7 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Schroder Oriental Income?

Schroder Oriental Income (LON:SOI) and The Biotech Growth Trust (LON:BIOG) are both small-cap asset management industry companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

The Biotech Growth Trust has a net margin of 96.47% compared to Schroder Oriental Income's net margin of 94.62%. The Biotech Growth Trust's return on equity of 48.26% beat Schroder Oriental Income's return on equity.

Company Net Margins Return on Equity Return on Assets
Schroder Oriental Income94.62% 39.20% -2.12%
The Biotech Growth Trust 96.47%48.26%12.39%

Schroder Oriental Income has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Schroder Oriental Income, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schroder Oriental Income£334.18M2.91£106.18M£144.693.01
The Biotech Growth Trust-£17.73M-16.92£83.83M£558.002.77

Schroder Oriental Income has a beta of 0.669, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, suggesting that its stock price is 40% less volatile than the broader market.

In the previous week, Schroder Oriental Income's average media sentiment score of 0.00 equaled The Biotech Growth Trust'saverage media sentiment score.

Company Overall Sentiment
Schroder Oriental Income Neutral
The Biotech Growth Trust Neutral

9.7% of Schroder Oriental Income shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.1% of Schroder Oriental Income shares are held by company insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

The Biotech Growth Trust beats Schroder Oriental Income on 6 of the 11 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Edinburgh Investment?

Edinburgh Investment (LON:EDIN) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Edinburgh Investment has a beta of 0.96137434, indicating that its stock price is 4% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, indicating that its stock price is 40% less volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to Edinburgh Investment's net margin of 89.72%. The Biotech Growth Trust's return on equity of 48.26% beat Edinburgh Investment's return on equity.

Company Net Margins Return on Equity Return on Assets
Edinburgh Investment89.72% 7.03% 6.69%
The Biotech Growth Trust 96.47%48.26%12.39%

Edinburgh Investment has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Edinburgh Investment, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edinburgh Investment£79.43M13.03£180.50M£55.9114.43
The Biotech Growth Trust-£17.73M-16.92£83.83M£558.002.77

In the previous week, Edinburgh Investment had 7 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 7 mentions for Edinburgh Investment and 0 mentions for The Biotech Growth Trust. Edinburgh Investment's average media sentiment score of 1.23 beat The Biotech Growth Trust's score of 0.00 indicating that Edinburgh Investment is being referred to more favorably in the media.

Company Overall Sentiment
Edinburgh Investment Positive
The Biotech Growth Trust Neutral

9.7% of Edinburgh Investment shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.4% of Edinburgh Investment shares are held by insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Edinburgh Investment beats The Biotech Growth Trust on 7 of the 13 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

Export
MetricThe Biotech Growth TrustAsset Management IndustryFinancial SectorLON Exchange
Market Cap£299.92M£2.38B£6.13B£2.80B
Dividend YieldN/A6.00%5.24%6.15%
P/E Ratio2.7762.0629.90366.69
Price / Sales-16.922,053.311,113.4086,225.18
Price / Cash87.7460.3394.2727.87
Price / Book1.431.396.617.75
Net Income£83.83M£265.27M£1.13B£5.89B
7 Day Performance3.07%0.69%0.78%0.45%
1 Month Performance22.50%-0.52%0.45%-1.40%
1 Year Performance109.49%8.72%17.24%65.24%

The Biotech Growth Trust Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,546
-0.8%		N/A+115.8%£299.92M-£17.73M2.77N/A
GSS
Genesis Emerging Markets Fund
N/AN/AN/AN/A£1.06B£250.40M6.181,626
AGT
AVI Global Trust
N/AGBX 261.50
flat		N/A+5.6%£1.04B£127.64M9.34N/A
VEIL
Vietnam Enterprise
N/AGBX 748.17
flat		N/A+27.4%£1.03B£81.16M18.70N/A
SOI
Schroder Oriental Income
N/AGBX 453
flat		N/A+52.2%£1.01B£334.18M3.13180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 7/2/2026 by MarketBeat.com Staff.
From Our Partners
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Urgent exposé on the "Mar-a-Lago Trade"
Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
What Happens to Your Assets If You Die Without a Will?
Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...
SmartAsset | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel